Covered recipient · General Payments record
NADINE EL ASMAR
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$2,193.53
- Reported across 47 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $729.40 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $338.34 | 5 |
| Alexion Pharmaceuticals, Inc. | $124.79 | 1 |
| DEXCOM, INC. | $60.31 | 1 |
| Lilly USA, LLC | $46.38 | 2 |
| BETA BIONICS, INC. | $34.97 | 1 |
| Amgen Inc. | $34.44 | 2 |
| Novo Nordisk AS | $27.77 | 1 |
| Abbott Laboratories | $23.25 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $23.06 | 1 |
| Astellas Pharma US Inc | $16.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.25 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125170939 | CMS |
| Alexion Pharmaceuticals, Inc. | $124.79 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093985606 | CMS |
| Amgen Inc. | $19.51 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115598313 | CMS |
| Amgen Inc. | $14.93 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115598321 | CMS |
| Astellas Pharma US Inc | $16.09 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139402469 | CMS |
| BETA BIONICS, INC. | $34.97 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087878791 | CMS |
| Dexcom, Inc. | $60.31 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324545 | CMS |
| Lilly USA, LLC | $25.21 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135260014 | CMS |
| Lilly USA, LLC | $21.17 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135175327 | CMS |
| Novo Nordisk Inc | $27.77 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097060661 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $23.06 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139162368 | CMS |
| SANOFI-AVENTIS U.S. LLC | $22.92 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139820903 | CMS |
| SANOFI-AVENTIS U.S. LLC | $129.11 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139820941 | CMS |
| SANOFI-AVENTIS U.S. LLC | $135.20 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139820953 | CMS |
| SANOFI-AVENTIS U.S. LLC | $22.94 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139820951 | CMS |
| SANOFI-AVENTIS U.S. LLC | $28.17 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139820983 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.